The Short-term Efficacy Study On Paclitaxei Combined With Lobaplatin In Locally Advanced, Stage â… B2-â…¡B Cervical Carcinoma Neoadjuvant Treatment

Object: we conducted a study to determine the short-term efficacy effort onpaclitaxel combined with lobaplatin in locally advanced, stage IB2-IIB cervicalcarcinoma neoadjuvant treatment.Methods: Between January12012to October312013,110patients with stageIB2to IIB cervical cancer were enrolled and selected to be one of the following fourtreatments:1).radical surgery alone(Arm RS)，25patients.2).intravenouschemotherapy paclitaxel135-175mg/m2plus lobaplatin30mg/m2at21days intervalfor two courses following by radical surgery (Arm IVCT TL),8patients.3).intravenous chemotherapy paclitaxel135-175mg/m2plus cisplatin80-100mg/m2at21days interval for subsequent courses following by radical surgery(Arm IVCTTP),60patients.4).paclitaxel135-175/m2plus carboplatin which the dose is measuredby the CR at21days interval for one or two courses following by radical surgery(ArmIVCT TC),17patients. After neoadjuvant treatment,all patents were evaluation forresponse and operability. The patients who were not suitable to surgery receivedconcurrent chemo-radiotherapy instead.Results:.Baseline characteristics were similarly distributed in the four arms. clinicaloverall response rate were98.82%(84/85).in three neoadjuvant chemotherapygroup,no patients achieved completely remission.,7patients(87.5%) achieved partialremission,and1patients(17.5%) achieved stable disease in PL group.47patients（78.3%）achieved PR,12patients（20%） achieved SD and1patient in(1.7%)achieved progressive disease in TP groups.15patients （88.2%）achieved PR,2patients （11.8%）achieved SD. No obvious difference in statistics(P=0.58)was foundin three chemotherapy groups. The volume of carcinoma tissue in the neoadjuvantchemotherapy groups is less than the RS group.No obvious difference in statistics was found in TL,TP,TC groups（P=0.98）.The diameter has statistics difference.（P<0.01）.96patients （96/110,87.3%）got adjuvant therapy after surgery.TL grouphad lower gastrointestinal reaction.while no difference in bone marrow depression,the hepatic function. the surgery time in stage IB2cervical cancer among RS,TP,TCgroups has obvious statistic difference.（RS vs TP, p=0.003，RS vs TC，p=0.007）But no difference in TP,TC groups(P=0.828)。Conclusions: Paclitaxel plus lobaplatin as a neoadjuvant scheme has nosignificant curative effects on outcomes of patients with stage IB2to IIB cervicalcarcinoma. However, neoadjuvant chemotherapy can significant reduce the volume ofthe carcinoma tissue. in stage IB2cervical cancer,the neoadjuvant chemotherapy hasthe tendency of reducing the time of the surgery. Due to the lower toxicity.the TLchemotherapy scheme is more acceptable to older and weaker patients.